HOOKIPA Pharma Inc
NASDAQ:HOOK
Intrinsic Value
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's i... [ Read More ]
The intrinsic value of one HOOK stock under the Base Case scenario is 0.3073 USD. Compared to the current market price of 0.8129 USD, HOOKIPA Pharma Inc is Overvalued by 62%.
Valuation Backtest
HOOKIPA Pharma Inc
Run backtest to discover the historical profit from buying and selling HOOK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
HOOKIPA Pharma Inc
Current Assets | 132.7m |
Cash & Short-Term Investments | 92.8m |
Receivables | 30.8m |
Other Current Assets | 9.2m |
Non-Current Assets | 13.2m |
PP&E | 12.3m |
Other Non-Current Assets | 864k |
Current Liabilities | 29.5m |
Accounts Payable | 11.2m |
Accrued Liabilities | 11.6m |
Other Current Liabilities | 6.8m |
Non-Current Liabilities | 11.8m |
Other Non-Current Liabilities | 11.8m |
Earnings Waterfall
HOOKIPA Pharma Inc
Revenue
|
53.6m
USD
|
Operating Expenses
|
-103.5m
USD
|
Operating Income
|
-49.9m
USD
|
Other Expenses
|
2.4m
USD
|
Net Income
|
-47.5m
USD
|
Free Cash Flow Analysis
HOOKIPA Pharma Inc
HOOK Profitability Score
Profitability Due Diligence
HOOKIPA Pharma Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
HOOKIPA Pharma Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
HOOK Solvency Score
Solvency Due Diligence
HOOKIPA Pharma Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
HOOKIPA Pharma Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HOOK Price Targets Summary
HOOKIPA Pharma Inc
According to Wall Street analysts, the average 1-year price target for HOOK is 4.42 USD with a low forecast of 3.03 USD and a high forecast of 5.25 USD.
Ownership
HOOK Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
HOOK Price
HOOKIPA Pharma Inc
Average Annual Return | -37.48% |
Standard Deviation of Annual Returns | 41.08% |
Max Drawdown | -98% |
Market Capitalization | 80.4m USD |
Shares Outstanding | 98 950 100 |
Percentage of Shares Shorted | 0.83% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2019-04-18. The firm is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its pipeline candidates include HB-200, HB-300, HB-700, HB-101, HB-101 and HBV Therapy. The HB-200 program consists of its arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by 16-positive (HPV16+). Its lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus HPV16+ cancers in a Phase I/II clinical trial. Its non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is for patients awaiting kidney transplantation in Phase II clinical trial.
Contact
IPO
Employees
Officers
The intrinsic value of one HOOK stock under the Base Case scenario is 0.3073 USD.
Compared to the current market price of 0.8129 USD, HOOKIPA Pharma Inc is Overvalued by 62%.